DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Joint Warfighter Medical
  4. Research Highlights/News
  5. 2024 Joint Warfighter Medical Research Program

Joint Warfighter Medical

NEWS RELEASE

Released: January 31, 2024

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Joint Warfighter Medical Research Program (JWMRP)
Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)

The FY24 Defense Appropriations Bill has not been signed into law. Although FY24 funds have not yet been appropriated for the JWMRP, the JWMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunity. This pre-announcement should not be construed as an obligation by the government.

The FY24 Defense Appropriations Act is anticipated to provide funding for the JWMRP to augment and accelerate progress toward critical Department of Defense (DOD) medical capability gaps and requirements through the continuation of research and development initiatives that were previously supported by DOD core and/or DOD congressionally-directed funding and that are close to achieving their objectives and yielding a benefit to military medicine. Funds shall be awarded following a review of military medical research and development gaps, as well as unfinanced medical requirements of the Services. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The JWMRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunity. This pre-announcement should not be construed as an obligation by the government. The FY24 JWMRP funding opportunity announcement for the following award mechanism will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcement is released.

Applications submitted to the FY24 JWMRP must address at least one of the following Focus Areas:

  • Broad spectrum and/or pathogen agnostic approaches to prevent and/or treat endemic or emerging infectious diseases of high operational impact
  • Preventative capabilities to promote the Warfighter’s physiological and cognitive (1) performance and readiness and (2) injury prevention
  • Solutions for semi-autonomous or autonomous medical care from the point of injury across the continuum of care, including support of triage, prolonged patient care, and transport in contested environments
  • Virtual/telehealth and decision support with artificial intelligence solutions to provide combat casualty care/prolonged care
  • Hemorrhage control and resuscitation solutions, including blood and blood products, and anti-shock therapeutics, to enable delivery of life-saving care across the continuum of care


Award Mechanism Eligibility Key Mechanism Elements Funding
Military Medical Research and Development Award (MMRDA) Extramural and intramural applicants
  • Independent investigators at all academic levels (or equivalent)
  • Pre-application is required; application submission is by invitation only.
  • Applicants must have already received DOD core or DOD congressionally-directed prior year funding for the same research and/or development project being proposed for logical continuation under this funding opportunity.
  • Funds shall not be used for new projects or for basic research.
  • Proposed projects must be a continuation of projects currently at Technology Readiness Level (TRL) 5 or above.
  • The MMRDA is intended to support a wide range of research projects, spanning late-stage preclinical studies, late-stage technology development efforts, technology demonstration, and translational research.
  • The MMRDA – Clinical Research/Trial Option is intended to specifically support clinical research/observational studies, all phases of clinical trials/interventional studies, and correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices, and technologies.
  • Must address at least one of the above FY24 JWMRP Focus Areas.
 MMRDA:
  • Maximum funding of $2.0M for total costs (direct plus indirect costs)
  • Maximum period of performance is 3 years
MMRDA – Clinical Research/Trial Option:
  • Maximum funding of $3.4M for total costs (direct plus indirect costs)
  • Maximum period of performance is 3 years

A pre-application is required and must be submitted through the Biomedical Research Application Portal (eBRAP) prior to the pre-application deadline. All applications must conform to the final funding opportunity announcements that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using Assistance Listing Number (ALN, formerly CFDA) 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the JWMRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).


Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil


Last updated Thursday, February 8, 2024